Randomized study of first-line pemetrexed (Pe) plus platinum (P) followed by second-line docetaxel (D) versus first-line DP followed by second-line Pe in advanced non-small cell lung cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004696

Enrollment

Unknown

Registered

2014-01-17

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

A:first-line pemetrexed (Pe) plus platinum (P) follo

B:first-line DP followed by second-line Pe

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) histologically or cytology confirmed inoperable non-squamous NSCLC; 2)newly diagnosed stage IV disease according to the staging system of the 2009 American Joint Committee on Cancer (AJCC); 3) an age of 18–75 years; 4) a Karnofsky Performance Status score =70%; 5) adequate bone marrow, liver and renal function; neutrophils = 1.5×109/L, platelets 80×109/L, hemoglobin =80g/L, AST and ALT =2× the upper limit of the institutional normal range, total bilirubin =1.25× the upper limit of the institutional normal range, and creatinine concentration =120 µmol/L;

Exclusion criteria

Exclusion criteria: 1) a history involving thoracic surgery, radiotherapy or chemotherapy; 2) pregnancy or lactation; 3) previous malignancy or other concomitant malignant disease; 4)allergy to any chemotherapeutics.

Design outcomes

Primary

Measure	Time frame
Overall surviva;	—

Secondary

Measure	Time frame
progression-free surviva;	—

Countries

China

Contacts

Public ContactSu Shengfa

sushengfa2005@163.com+86 851 6513076

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026